文献速递围术期管理与 ERAS

雷帕霉素药物涂层支架治疗V1段椎动脉狭窄的疗效与安全性

[Efficacy and safety of rapamycin-eluting stents for vertebral artery stenosis in the V1 segment: a real-world retrospective cohort study].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2026-01-01

这项回顾性队列研究分析了191例V1段椎动脉狭窄患者,比较雷帕霉素药物涂层支架(DES,n=93)与裸金属支架(BMS,n=98)的疗效与安全性。两组围手术期技术成功率和30天脑卒中率无显著差异(P>0.05),但DES组术后12个月支架通畅率(94.5% vs. 83.2%,P=0.016)和免于脑卒中率(97.8% vs. 89.5%,P=0.020)均显著优于BMS组。

要点

  • DES组12个月支架通畅率94.5%,显著高于BMS组的83.2%(P=0.016)。
  • DES组12个月免于脑卒中率97.8%,显著高于BMS组的89.5%(P=0.020)。
  • 两组围手术期技术成功率和30天脑卒中率无显著差异,均无死亡病例。

核心结论

  • 在V1段椎动脉狭窄治疗中,DES围手术期安全性良好,术后12个月支架通畅率和免于脑卒中率优于BMS。
  • 中远期疗效仍需继续随访观察。

研究设计与样本

  • 回顾性队列研究,纳入2023年1月至2024年8月单中心191例V1段椎动脉狭窄接受支架植入的患者。
  • 男性161例,女性30例,年龄(68±8)岁(范围:47~86岁);V1段>70%重度狭窄146例。
  • 按支架类型分为DES组(n=93)和BMS组(n=98),两组术前基线资料差异均无统计学意义(P值均>0.05)。

主要发现

  • DES组手术时间(63±31)min(范围:24~120 min),技术成功率98.9%(92/93),围手术期30天内脑卒中发生率1.1%(1/93)。
  • BMS组手术时间(58±24)min(范围:26~110 min),技术成功率100%,围手术期30天内脑卒中发生率2.0%(2/98)。
  • 两组手术时间、技术成功率和围手术期脑卒中发生率差异均无统计学意义(P值均>0.05),两组均无死亡病例。
  • DES组91例、BMS组95例获得12个月以上随访;DES组12个月通畅率94.5%(86/91)高于BMS组83.2%(79/95),χ²=5.838,P=0.016。
  • DES组术后1年内免于脑卒中发生率97.8%(89/91)高于BMS组89.5%(85/95),χ²=5.410,P=0.020。

临床怎么用

  • 对于V1段椎动脉狭窄患者,DES可作为支架选择之一,围手术期安全性良好。
  • DES在12个月支架通畅率和免于脑卒中方面优于BMS,但需继续随访评估中远期疗效。

局限性

  • 本研究为单中心回顾性队列研究,可能存在选择偏倚。
  • 随访时间仅12个月,中远期疗效尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of rapamycin-eluting stents in treating stenosis of the vertebral artery V1 segment. Methods: This retrospective cohort study analyzed 191 patients with vertebral artery V1 segment stenosis who underwent stent implantation at our institution between January 2023 and August 2024. There were 161 male cases and 30 female cases. The age of the cohort was (68±8) years (range: 47 to 86 years). Patients were divided into two groups based on the stent type: the rapamycin-eluting stent (DES) group (n=93) and the bare-metal stent (BMS) group (n=98). Baseline characteristics showed no significant differences between the groups. Outcome measures included technical success rate, periprocedural (30-day) complications (stroke, mortality), and follow-up outcomes at 12 months (stent patency, stroke recurrence). Statistical analyses were performed using the independent sample t test, χ² test, or Fisher's exact test, as appropriate. Survival analysis was conducted using the Kaplan-Meier method. Results: The operation time of patients in the DES group was (63±31) min (range: 24 to 120 min), with a technical success rate of 98.9% (92/93), and the periprocedural stroke rate within 30 d was 1.1% (1/93). The operation time of the BMS group was (58±24) min (range: 26 to 110 min), with a technical success rate of 100%, and the incidence of stroke within 30 d of the operation was 2.0% (2/98). There were no statistically significant differences in operation time, technical success rate, and the periprocedural stroke rates between the two groups (all P>0.05), and no deaths occurred in either group. A total of 91 cases in DES group and 95 cases in BMS group were followed up for more than 12 months. The Kaplan-Meier survival analysis results showed that the patency rate at 12 months after operation, the DES group demonstrated significantly higher stent patency rates (94.5%(86/91) vs. 83.2%(79/95), χ²=5.838,P=0.016) and a higher stroke-free survival rate (97.8%(89/91) vs. 89.5%(85/95), χ²=5.410,P=0.020) compared to the BMS group. Conclusions: In the treatment of V1 segment vertebral artery stenosis, DES demonstrates a favorable perioperative safety profile, significantly higher stent patency and a lower stroke recurrence rate compared to BMS at 12 months follow-up. Further extended follow-up is required to evaluate their long-term efficacy. 目的: 探讨雷帕霉素药物涂层支架治疗V1段椎动脉狭窄的临床效果。 方法: 本研究为回顾性队列研究。回顾性分析2023年1月至2024年8月清华大学北京清华长庚医院血管外科收治的因V1段椎动脉狭窄接受支架植入手术治疗的191例患者资料。男性161例,女性30例,年龄(68±8)岁(范围:47~86岁)。其中V1段>70%重度狭窄146例。根据应用支架不同,分为雷帕霉素药物涂层支架组(n=93),传统裸金属支架组(n=98)。两组术前基线资料的差异均无统计学意义(P值均>0.05)。收集两组患者手术情况、围手术期并发症情况及死亡情况,以及术后12个月随访情况。组间比较采用独立样本t检验、χ2检验或Fisher确切概率法。采用Kaplan-Meier法绘制患者术后支架通畅及免于脑卒中发生曲线。 结果: 雷帕霉素药物涂层支架组患者的手术时间为(63±31)min(范围:24~120 min),技术成功率为98.9%(92/93),围手术期30 d内脑卒中发生率为1.1%(1/93)。传统裸金属支架组手术时间(58±24)min(范围:26~110 min),技术成功率100%,围手术期30 d内脑卒中发生率为2.0%(2/98)。两组手术时间、技术成功率、围手术期脑卒中发生率的差异均无统计学意义(P值均>0.05),两组均未出现死亡病例。雷帕霉素药物涂层支架组91例,传统裸金属支架组95患者获得12个月以上随访。患者均获得12个月以上随访,雷帕霉素药物涂层支架组术后12个月通畅率高于传统裸金属支架组[94.5%(86/91)比83.2%(79/95),χ²=5.838,P=0.016],术后1年内免于脑卒中发生率亦高于传统裸金属支架组[97.8%(89/91)比89.5%(85/95),χ²=5.410,P=0.020]。 结论: 雷帕霉素药物涂层支架在治疗V1段椎动脉狭窄围手术期安全性高,术后12个月支架通畅率及免于脑卒中发生率优于普通金属裸支架,中远期疗效仍需继续随访观察。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao KQ, Zhao JL, Jiang C, et al. [Efficacy and safety of rapamycin-eluting stents for vertebral artery stenosis in the V1 segment: a real-world retrospective cohort study]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 41881799. doi:10.3760/cma.j.cn112139-20250820-00409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。